Tumor mutational and indel burden: a systematic pan-cancer evaluation as prognostic biomarkers

BACKGROUND: Tumor mutational burden (TMB) has been widely studied as a predictive biomarker of response to immune checkpoint inhibitors (ICIs). Besides, evidence suggests frameshift indels are a highly immunogenic mutational class and thus a potentially superior biomarker. However, the general progn...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Transl Med
Autors principals: Wu, Hao-Xiang, Wang, Zi-Xian, Zhao, Qi, Chen, Dong-Liang, He, Ming-Ming, Yang, Lu-Ping, Wang, Ying-Nan, Jin, Ying, Ren, Chao, Luo, Hui-Yan, Wang, Zhi-Qiang, Wang, Feng
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6944566/
https://ncbi.nlm.nih.gov/pubmed/31930041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2019.10.116
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars